Arnon Nagler, M.D., M.Sc., served for many years as a director of both the Division of Hematology and the Bone Marrow Transplantation and Cord Blood Bank at the Chaim Sheba Medical Center, and Professor of Medicine at The Tel Aviv University, Israel.
Prof. Nagler received his medical training at the Hebrew University-Hadassah Medical School, Jerusalem, Israel, specializing in Internal Medicine and Haematology at the Rambam Medical Center, Haifa, and in Hematopoiesis (MSc) in TA University, Israel. He carried out a Postdoctoral research fellowship in hematology and bone marrow transplantation at “Stanford University Hospital” Palo Alto, CA, in the USA, from 1986 to 1990.
Prof. Nagler has been working in the fields of bone marrow transplantation for haematological malignancies, for the last 25 years. Prof. Nagler is one of the pioneeres of the non myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders (Blood 1998). His main contributions and scientific interests include hematpoietic stem cell transplantation, haematological malignancies, cord blood biology and transplantation and adoptive cell-mediated immunotherapy including NK cell biology.
Prof. Nagler established the first public cord blood bank in Israel and performed the first cord blood transplantations from related and unrelated donors in genetic and malignant hematological diseases in Israel.
Prof. Nagler is active member of the EBMT since 1993. In 2001 EBMT Annual meeting (Maastricht, the Netherland) his study on IL-18 for GVHD in mice model was chosen for presentation at the presidential symposium. Over the years he was invited speaker in several of the EBMT meetings. Dr Nagler served as the leader of the Alternative donor subcommittee of the ALWP of the EBMT from 2008-2010 and from 2010 he is the leader of the RIC subcommittee of the ALWP of the EBMT.
Prof. Nagler serves on the Board of Directors of Netcord organization of cord blood banks and was the Netcord Threasurer from 2010-2013. Prof. Nagler is a member of multiple national and international societies and committees in the field. He serves on the Editorial Board of several journals and is the stem cell transplantation Section Editor for Leukemia.
Prof. Nagler has written numerous original articles, reviews and chapters for top rank peer-review journals including JCO, Blood, JEM, JI, EJI ,Leukemia and many others and is the principal investigator for a multiple clinical studies including first to human trials with novel molecules like Pidilizumab (McAb against PD-1) and BL8040 (novel CXCR4 antagonist). Prof. Nagler is inventor of multiple patents including for purging of BM with NK cells and inhibition of fibrosis by Halofuginon.
Prof. Nagler has received several awards including the best scientific abstract award of the ASBMT/CIBMR Tandem meeting (2004) and the best clinical abstract award of the NMDP Council Meeting (2004). In addition, Prof. Nagler is a popular speaker and has made numerous, invited, international presentations and many Oral presentations on almost annual basis in all international transplantation and hematology meetings – ASH,ASBMT/CIBMTR, EBMT, EHA, Exp Hematology (including a presentation at the presidential symposium) and invited presentation at the Gordon conference (Boston USA).
Conditions and treatment
- Surgical oncology
- Cell biology
- Adoptive cell mediated immunotherapy
- Fibrotic disorders
- Cord blood biology
- NK and CTL activity
- Hemato-oncological malignancies
- President of the Hemato-Oncology Center, Sheba Medical Center
- Director of Bone Marrow transplantation and Cord Blood Bank, Sheba Medical Center
- Professor of Medicine at the Tel Aviv University
- Chair of the ALWP of the EBMT-since 2014
- coChair Scientific Council of the EBMT –since 2016
- Active member of the EBMT since 1993
- Leader of the Alternative donor subcommittee of the ALWP of the EBMT from 2008-2010
- Leader of the RIC subcommittee of the ALWP of the EBMT –2010-2014
- Member of multiple national and international societies and committees
- Serves on the Editorial Board of several BMT and Hematology Journals and is a Section Editor for Leukemia
- Co-Chair Molecular Markers Subcommittee, the ALWP of the EBMT
- Vice-chair of the ALWP of the EBMT: 2018-2022
- One of the pioneers of the non-myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders (Blood 1998)
- Established the first public cord blood bank and performed the first cord blood transplantation in Israel
- Guest professor Zhejiang university, Hangzhou, China- September 2023
Education and Training
- M.D. certification from the Hebrew University-Hadassah Medical School, Jerusalem
- Specialized in Internal Medicine and Haematology at the Rambam Medical Center, Haifa
- MSc. specialization in Hematopoiesis in TA University, Israel
- Postdoctoral research fellowship in hematology and bone marrow transplantation at "Stanford University Hospital" Palo Alto, CA, in the USA, from 1986 to 1990.
- Internal Medicine
Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort.
Request a consultation
Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone.
We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.
Request a consultation and a Sheba Case Manager will contact you shortly: